ERBB2 and gastroesophageal junction adenocarcinoma: CheckMate-649 was a Phase III randomized, open-label trial in adults with first-line, unresectable, HER2-, advanced or metastatic G/GEJ adenocarcinomas, regardless of their PD-L1 CPS score [3].